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Myasthenia  gravis is a  disease characterized  by extreme muscular weakness and 
flaccid  paralysis.  Many  lines  of evidence  indicate  that  this  condition  arises  as  a 
consequence of an autoimmune response directed against the nicotinic acetylcholine 
receptor (AChR) l of the neuromuscular junction (1-3). Mice immunized with AChR 
purified from the electrogenic organ of Torpedo californica  form anti-AChR antibodies 
and often develop muscular weakness and  flaccid paralysis which  closely resembles 
human  myasthenia gravis.  This condition,  termed experimental  myasthenia  gravis 
(EMG), is strain dependent  in that the frequency of weakness and paralysis is much 
greater in some strains than  in others  (4, 5).  Mice of the C57BL/6,  SJL, and AKR 
strains exhibit high susceptibility with 50-70% of the animals immunized developing 
muscular weakness and paralysis. Other strains such as BALB/c, C3H/He, and SWR 
display low susceptibility with 0-15% of the animals immunized developing muscular 
weakness. This strain-dependent  difference in susceptibility might reflect differences 
in the immune system or differences in the neuromuscular junction. The observation 
(5)  that nonimmunized mice from high- and low-susceptibility strains were indistin- 
guishable with respect to their sensitivity toward the cholinergic antagonist  d-tubo- 
curarine suggested that the strain dependence was a consequence of something other 
than  a  difference  at  the  neuromuscular junction.  In  this  paper,  we  examine  the 
possibility  that  susceptibility  to  muscular  weakness  after  immunization  with  T. 
californica  AChR  is determined  by regions of the  mouse genome known  to regulate 
immune responsiveness. 
In  the  mouse,  two  loci  have been  identified  that  participate  in  determining  an 
individual's  ability  to  respond  to  any  given  antigen:  the  major histocompatibility 
complex (I-I-2) and the region that contains the structure genes for the constant region 
of immunoglobulin  heavy chains  (IgCH)  (6-9).  The H-2 region  is  located on chro- 
mosome  17,  and codes for the major histocompatibility antigens, of the mouse  (10- 
* Supported by  National Institutes of Health  grant NS  13546-03 and  grants from the  Muscular 
Dystrophy Associations of America and the Whitehall Foundation. 
:~ Supported by postdoctoral fellowships from the Muscular Dystrophy  Associations  of America and the 
National Institutes of Health (NS 05715. 
I Abbreviations usedin thispaper: AChR, nicotinic acetylcholine  receptor(s); EMG, experimental myasthenia 
gravis; IgCH region, region that contains the structural genes for the constant region of immunoglobulin 
heavy chains; IgVH region, region that contains the structural genes for the variable region of immuno- 
globulin heavy chains. 
J. Exp. MED. © The Rockefeller  University Press • 0022-1007/80/09/0507/14 $1.00  507 
Volume 152  September 1980  507-520 508  GENETICS OF SUSCEPTIBILITY  TO  MYASTHENIA GRAVIS 
13). This highly polymorphic locus is known to specify gene products that subserve 
antigen recognition and cell-cell recognition phenomena. The IgCn region is located 
on chromosome 12  (14) and contains the structural  genes for the constant region of 
immunoglobulin heavy chains. This locus is smaller than H-2 and is closely linked to 
the region that contains the structural genes for the variable region of immunoglobulin 
heavy chains (IgVn)  (15,  16). The availability of H-2- and IgCn-congenic strains of 
mice has afforded us an opportunity to examine the influence of both of these regions 
on the development of muscular weakness and paralysis after immunization with  T. 
californica AChR. 
Materials and Methods 
Mice  of the  BALB/c, BALB.B10, BALB/K, C.B20, C.B20B, and  BAB/14 ,strains  were 
provided  by Dr.  Melvin  Cohn of The Salk Institute,  San Diego, Calif.  Mice of the strains 
CWB/20 and SJA/9 were provided  by Dr. Lenore Herzenberg  and Dr. Leonard Herzenberg 
of Stanford University Medical School, Stanford, Calif. Mice of the strain C57BL/Ka.Ig  a (B.C/ 
8) were provided by Dr. Roy Riblet of the Fox Chase Cancer Research Institute,  Philadelphia, 
Pa. B6CF1 and C3B6Fa mice were bred at The Salk Institute from breeder stock obtained from 
The Jackson Laboratory, Bar Harbor, Maine.  All other mice used were purchased  from The 
Jackson Laboratory. 
The methods used for the purification  of T. californica AChR and the immunization of mice 
have  been  described  in  detail  (5). Mice  were judged paralyzed or normal  using  the  assays 
described previously (5). The significance level of differences in the frequency of EMG between 
strains of mice was determined  by use ofa 2 × 2 X  "2 contingency test corrected for continuity as 
described by Snedecor and Cochran (14). The P values reported  indicate  the probability that 
differences in the frequency of muscular  weakness between  two strains  of mice occurred  as a 
consequence of sampling error. The frequencies given for the C57BL/6J, A/J, C3H/HeJ, SJL/ 
J,  and  BALB/cke  strains  were  reported  previously  (5)  and  are  presented  for  purposes  of 
comparison. 
Results 
Effect of Loci That Regulate Immune Responsiveness on the Frequency of Muscular  Weakness 
and Paralysis.  The ability of mice to respond to a  variety of antigens is known to be 
determined by immune response (Ir) genes linked to alleles 2 of the H-2 complex and 
by genes linked to allotype alleles of the IgCn region locus. To test the possibility that 
susceptibility to EMG is similarly determined by alleles of these loci, the frequency of 
muscular weakness  and  flaccid paralysis was  measured  in  strains  of mice congenic 
with those previously found to be high or low responders. A  list  of the strains tested 
and their relevant characteristics is given in Table I. The first  question we considered 
was  whether  or  not  mice  constructed  with  the  H-2  and  IgCn  haplotypes  of high 
susceptibility strains, and the backgrounds (i.e., all loci not linked to H-2 or IgCn) of 
low susceptibility  strains,  exhibited  high  susceptibility  toward -the  development  of 
EMG. The C57BL/6 and C57BL/10 strains both exhibit  high susceptibility  (-70% 
develop  muscular  weakness  and  paralysis)  and  both  possess  the  H-2  b  and  Ig-1  b 
haplotypes. The BALB/c and C3H/HeJ strains, on the other hand, possess  the H-2  d 
and  H-2  k haplotypes, respectively, share  the  Ig-1  a haplotype, and  both exhibit  low 
susceptibility (~7-1 I% develop muscular weakness and paralysis). If susceptibility to 
myasthenia  gravis  is  determined  by  regions  of the  mouse  genome  that  regulate 
2  The terms "allele" and "haplotype" are used interchangeably to specify  a group of genes closely linked 
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TABLE  I 
H-2- and AUotype-congenic Strains of Mice 
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Inbred 
Strain  H-2  IgCH  background  Source  of IgCrl  Source  of H-2  Reference 
1 BALB/cke  d  a  BALB/c  BALB/c  BALB/c  12, 15 
2 C.B20  d  b  BALB/c  C57BL/Ka  BALB/c  12, 15 
3 BAB/14  d  b/a  BALB/c  C57BL/Ka  BALB/c  12, 15 
4 C.B20B  b  b  BALB/c  C.B20  BALB.BIO  12, 18 
5 BALB.B10  b  a  BALB/c  BALB/c  C57BL/10Sn  12, 18 
6 BALB.K  k  a  BALB/c  BALB/c  C3H  12 
7 C57BL/6J  b  b  C57BL/6J  C57BL/6J  C57BL/6J  12, 15 
8 C57BL/10Sn  b  b  C57BL/10Sn  C57BL/10Sn  C57BL/10Sn  12, 15 
9 BI0.A/SgSn  a  b  C57BL/10  C57BL/10  A/WrSnSg  9, 12 
10  BIO.D2/nSn  d  b  C57BL/10  C57BL/10  DBA/2  12, 15 
11  C57BL/Ka.Ig  ~  b  a  C57BL/Ka  BALB/c  C57BL/Ka  12, 15 
12 C3H/HeJ  k  a  C3H/HeJ  C3H/HeJ  C3H/HeJ  12, 15 
13  C3H.SW/Sn  b  a  C3H/HeDiSn  C3H/HeDiSn  Swiss  12, 16 
14 CWB/20  b  b  C3H.SW/Sn  C57BL/Ka  C3H.SW  12, 16 
15  SjL/j  s  b  SJL/j  SJL/J  SJL/J  12, 15 
16 SJA/9  s  a  SJL/J  BALB/c  SJL/J  12, 16 
17 AKR/J  k  d  AKR/J  AKR/J  AKR/J  12, 15 
18 A/J  a  e  A/J  A/J  A/J  12, 15 
TABLE II 
Effect of the H-2 b and Ig-I b Haplotypes  on the Frequency of Muscular  Weakness after Immunizotion  with 
T. californica AChR* 
Strain  Background  H-2  Ig- 1  Number  Number  Frequency 
tested  EMG  of paralysis 
1  C57BL/6J  C57BL  b  b  45  32  0.71 
2  C57BL/10Sn  C57BL  b  b  20  14  0.70 
3  BALB/cke  BALB  d  a  56  4  0.07 
4  C3H/HeJ  C3H  k  a  35  4  0.11 
5  C.B20B  BALB  b  b  24  16  0.67 
6  CWB/20  C3H  b  b  20  15  0.75 
* P values for differences in the frequency of paralysis between strains are given in the text. 
immune responsiveness, then mice which differ from BALB/c and C3H/He  only in 
that  the  H-2  b  and  Ig-I  b  haplotypes  replace  the  H-2  a,  H-2  k,  and  Ig-1 a  haplotypes 
should  exhibit  high  susceptibility.  Conversely,  if susceptibility  is  determined  by 
regions of the mouse genome other than those regulating immune responsiveness (e.g., 
those controlling the neuromuscular  junction), then mice constructed with the BALB 
or C3H background and the H-2  b and Ig-1 b haplotypes should exhibit low suscepti- 
bility. When the  frequency of EMG  was  determined for  two  strains of mice  that 
possess these characteristics, C.B20B  (BALB background; H-2  b, Ig-1 b) and CWB/20 
(C3H background; H-2  b, Ig-lb), both were found to exhibit high susceptibility (Table 
II). Thus, the introduction of the  H-2  b and Ig-1 b haplotypes onto the BALB  back- 
ground increased (P <  0.005) the frequency of muscular weakness and paralysis from 
7%  for BALB/c  (H-2  d,  Ig-1  a)  to 67%  for C.B20B  (H-2  b, Ig-lb). Similarly, the intro- 
duction of the H-2  b and Ig-1 b haplotypes onto the C3H background correlated with 
an increase (P <  0.005) in the frequency of myasthenic weakness from  11% for C3H/ 510  GENETICS  OF SUSCEPTIBILITY  TO  MYASTHENIA GRAVIS 
Heal (H-2  k, Ig-I  a) to 75% for CWB/20 (H-2 b, Ig- lb). Thus, the H-2  b, Ig-1  b genotype is 
associated  with  high  susceptibility  to  EMG  in  four  strains  of  mice  (C57BL/6, 
C57BL/10,  CWB/20,  and  C.B20B)  derived  from  three  dissimilar  backgrounds 
(C57BL, C3H, and BALB). These studies demonstrate  that susceptibility  to EMG is 
a  heritable  trait determined  by regions of the genome that are linked to, or identical 
with, those that regulate immune responsiveness, and that by simply inserting the H- 
2  b-  and  Ig-lb-bearing  chromosomes,  low-susceptibility  strains  can  be  converted  to 
high-susceptibility strains. 
Effect  of the  H-2  Locus  on  the  Frequency  of Muscular  Weakness and Paralysis.  Further 
studies were conducted to assess the relative contributions of the H-2 and IgCn loci. 
Initially, we sought to determine  whether or not high-susceptibility  strains could be 
converted  to  low-susceptibility  strains  by  substitutions  at  the  H-2  locus.  The 
C57BL/6 and C57BL/10 strains  both  exhibit  high susceptibility  and  both  bear the 
H-2  b,  Ig-1  b  genotype.  BALB/e  and  A/J  mice,  on  the  other  hand,  exhibit  low 
susceptibility and possess the H-2  d and H-2  a haplotypes, respectively. If susceptibility 
to  myasthenic  weakness  is  determined  only by the  H-2  haplotype,  then  mice that 
differ  from C57BL/6  or C57BL/10  only in  that  the  H-2  a or H-2  d haplotypes  have 
been  substituted  for  the  H-2  b  haplotype,  should  exhibit  low  susceptibility.  The 
frequency of myasthenic weakness and paralysis was determined  for two strains that 
possess these characteristics:  B 10.D2/nSn  (H-2d), and B 10.A/SgSn  (H-2a). As can be 
seen  in  Table  III, 47%  of the  B10.D2/nSn  and  38%  of the  B10.A/SgSn  become 
paralyzed. Thus, although the H-2  a and H-2  d haplotypes probably influenced suscep- 
tibility  (P =  0.179  for B10.D2/nSn;  P  =  0.079  for B10.A/SgSn)  by converting high 
responders to intermediate responders, neither haplotype conferred low susceptibility. 
These studies suggested  that  other loci beside  H-2 are  involved in  the  regulation  of 
susceptibility to EMG. 
In  reciprocal  studies,  we  sought  to  determine  whether  or  not  low-susceptibility 
strains could be converted to high-susceptibility strains as a  consequence of substitu- 
tions made  at  the  H-2  locus. The  BALB/c and  C3H/HeJ  strains  both  exhibit  low 
susceptibility (~ 7-11% developed paralysis) and possess the H-2  d and H-2  k haplotypes, 
TABLE III 
Effect of H-2 Haplotypes on the Frequency of Muscular Weakness after Immunization with T. californica 
AChR* 
Number  Number  Frequency  Strain  Background  H-2  tested  EMG  of paralysis 
1  C57BL/6J  C57BL  b  45  32  0.71 
2  C57BL/10Sn  C57BL  b  20  14  0.70 
3  B  10.D2/nSn  C57BL  d  15  7  0.47 
4  B 10.A/SgSn  C57BL  a  13  5  0.38 
5  A/J  A/J  a  15  2  0.13 
6  BALB/cke  BALB  d  56  4  0.07 
7  BALB.B10  BALB  b  18  9  0.50 
8  BALB.K  BALB  k  13  2  0.15 
9  AKR/J  AKR  k  28  14  0.50 
10  C3H/HeJ  C3H  k  35  4  0.11 
11  C3H.SW/Sn  C3H  b  25  15  0.60 
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respectively. If susceptibility is determined by the H-2 locus, then the introduction of 
the H-2  b haplotype (found in the high-susceptibility C57BL/6 and C57BL/10 strains) 
onto these backgrounds should confer high susceptibility. As can be seen in Table III, 
the BALB.B 10 strain (BALB background; H-2  b) exhibited intermediate susceptibility 
and the C3H.SW strain (C3H background; H-2  b) exhibited high susceptibility. Thus 
the H-2  b haplotype had a significant effect (P <  0.005) and increased the frequency 
of weakness and paralysis from 7% for BALB/c (H-2  d) to 50% for BALB.B 10 (H-2b). 
In the case of the C3H strain, the substitution of the H-2  b haplotype (C3H.SW)  for 
the  H-2  k haplotype  (C3H/HeJ)  markedly  affected susceptibility  (P <  0.005)  and 
increased the frequency of EMG from 11% (C3H/HeJ) to 60% (C3H.SW). 
Previous studies (4, 5) revealed that a high-susceptibility strain (AKR) and a low- 
susceptibility strain  (C3H/HeJ)  can  share  the  same  haplotype  (H-2k).  To  further 
explore this issue, we measured the frequency of paralysis in another strain of mice 
that possess  the H-2  k haplotype, BALB.K. This strain differs from the low responder 
BALB/c only in that the H-2  k haplotype replaced the H-2  d haplotype. As Table III 
indicates that only 15% of the BALB.K mice became paralyzed, the substitution of 
H-2  k for H-2  d on the BALB background, therefore, did not significantly (P =  0.705) 
increase the frequency of muscular weakness or paralysis. 
From these studies,  it was concluded that  the H-2 locus can markedly influence 
susceptibility. In particular,  the H-2  b allele was always found to be associated with 
intermediate  or  high  susceptibility,  and  the  introduction  of the  H-2  b  haplotype 
imparted increased susceptibility to the low susceptibility C3H and  BALB/c back- 
grounds.  However, the observation that  replacement of the H-2  b haplotype on the 
C57BL/6 and C57BL/10 backgrounds  (B10.D2/sSn and  B 10.A/SgSn)  reduced the 
incidence of myasthenia gravis to intermediate values, but did not confer resistance 
(low susceptibility) toward the development of muscular weakness, suggested that the 
H-2 locus is not the only factor involved. Because different inbred strains that share 
the same haplotype were found to differ significantly with respect to the frequency of 
muscular weakness and paralysis  (e.g.,  BALB/c and  B10.D2/nSn:  H-2d; C3H/HeJ, 
BALB.K, and AKR:  H-2k; B10.A/SgSn and A/J:  H-2a), it must  be concluded that 
other factors beside the H-2 type participate in conferring susceptibility or resistance 
to myasthenic weakness. 
Effect  of Allotype  on  the  Frequency of Muscular  Weakness and  Paralysis.  The  high- 
susceptibility strains C57BL/6, C57BL/10, C.B20B, CWB/20, and SJL/J all possess 
the  Ig-I b haplotype, which  is  not  present  in  any  of the  low-susceptibility strains. 
Similarly the Ig-1 a haplotype is present on the low-susceptibility strains BALB/c and 
C3H/HeJ  and  is  found only in  high-susceptibility  strains  that  also  bear the  H-2  b 
haplotype. To explore the influence of IgCH alleles on susceptibility to myasthenia 
gravis, the frequency of muscular weakness was measured in the SJA/9 and C57BL/ 
Ka.Ig  ~ strains of mice; these strain are identical to the high susceptibility strains SJL 
and C57BL/6, respectively, with the exception that the Ig-1 ~ haplotype replaces the 
Ig-1 b haplotype. If susceptibility to EMG is determined by the IgCH locus alone, then 
SJA/9 and C57BL/6Ka.Ig  ~ mice should exhibit low susceptibility. Conversely, if the 
IgCH locus is not involved in susceptibility, then these strains should develop weakness 
with the same frequency as the high-responder SJL and C57BL/6 strains. If both the 
H-2  locus  and  the  IgCH  locus  determine  susceptibility,  the  C57BL/Ka.Ig  a  strain 
should exhibit intermediate or high susceptibility because it bears the H-2  b allele, and 512  GENETICS OF SUSCEPTIBILITY TO  MYASTHENIA  GRAVIS 
SJA/9  (H-2  s)  could  exhibit  high,  intermediate,  or  low  susceptibility.  As  Table  IV 
indicates, 27% of the SJA/9 mice became paralyzed, indicating that the substitution 
of the Ig-1  a haplotype for the Ig-1 b haplotype significantly (P =  0.009)  reduced the 
frequency of weakness and paralysis. In the case of C57BL/Ka.Ig  a,  53%  of the mice 
became paralyzed; thus the substitution of the Ig-1 s haplotype for the Ig-1 b haplotype, 
did not significantly (P =  0.37)  affect the incidence of weakness and paralysis. This 
result suggested that  the influence of the H-2 b haplotype is greater than  that  of the 
Ig-1 ~ haplotype and can mask any effect resulting from the ailotype substitution. 
In reciprocal experiments, we sought to determine whether the introduction of the 
high-susceptibility Ig-1  b haplotype onto  the low-susceptibility BALB/c  background 
converted  BALB  to  a  high-responder  strain.  The  C.B20  strain  is  identical  to 
BALB/c with the exception that the Ig-1 b haplotype replaces the Ig-I  ~ haplotype. As 
Table IV indicates, 30% of the C.B20  mice became paralyzed, and this represents a 
fourfold increase (P =  0.017)  in the frequency of EMG relative to the congenic BALB/ 
c  strain.  This  result  again  indicated  that  alleles  linked  to  the  IgCn  locus  can 
significantly modulate susceptibility to EMG. 
Finally, an effort was made to localize the elements linked to the Ig-1 b allele that 
correlate with  susceptibility to  EMG.  The  BAB/14  strain  is identical to  the C.B20 
strain  with  the exception that  there is a  crossover between  the IgCn  and  the IgVn 
locus (9,  19, 20). Thus BAB/14 has the Ig-1  b IgCn-region allotype markers of C57BL/ 
6 and IgVn-region idiotypic markers of BALB/c. If susceptibility to EMG is influenced 
by the IgCn region only, the frequency of myasthenia gravis in BAB/14 mice should 
TABLE  IV 
Effect of lgC~ Haplotypes on the Frequency of Muscular  Weakness after Immunization  with  T. californica 
AChR* 
Strain  Background  Ig- 1  Number  Number  Frequency 
tested  EMG  of paralysis 
1  SJA/9  SJL  a  22  6  0.27 
2  SjL/j  SJL  b  45  29  0.64 
3  C57BL/Ka.Ig  a  C57BL/Ka  a  l 5  8  0.53 
4  C57BL/6  C57BL/6  b  45  32  0.71 
5  C.B20  BALB/c  b  31  9  0.29 
6  BAB/14  BALB/c  b/a  28  0  0 
7  BALB/c  BALB/c  a  56  4  0.07 
* P values for differences in the frequency of paralysis between strains are given in the text. 
TABLE  V 
Effect of Heterozygosity on the Frequency of Muscular  Weakness after Immumzation  with  T. californica 
AChR* 
Maternal  Paternal 
Strain  Strain  Strain  H-2  Ig- 1 
Fre-  Num-  Num- 
ber  ber  quency 
of  tested  EMG  paralysis 
l  CB6F1/J  BALB/cJ  C57BL/6J  d/b  a/b 
2  B6CFj  C57BL/6J  BALB/cke  b/d  b/a 
3  C3B6F1  C3H/HeJ  C57BL/6J  k/b  a/b 
15  6  0.40 
16  6  0.38 
33  14  0.42 
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not differ from that in C.B20 mice. Conversely, if susceptibility is determined by the 
IgVn  region, BAB/14 mice should  exhibit  low susceptibility, as  found in  BALB/c 
mice.  As  seen  in  Table  IV,  not  a  single  BAB/14  mouse  developed  weakness  or 
paralysis. This result suggests, therefore, that the elements linked to the IgCri region 
that correlate with increased susceptibility to EMG are located near the IgVH region 
of chromosome 12. 
Effect  of Heterozygosity  on  the  Frequency of Muscular  Weakness  and  Paralysis.  The 
frequency of muscular weakness and flaccid paralysis was determined for three strains 
of F1 mice produced by matings of high-susceptibility strains with low-susceptibility 
strains. If susceptibility to EMG is a dominant trait, then mice that are heterozygous 
at the H-2 and IgCn loci and that bear the high-susceptibility H-2  b and Ig-1 b alleles 
should  exhibit  high  susceptibility.  Conversely,  if low  susceptibility  (resistance)  to 
EMG  is a  dominant  trait,  then  mice that  are heterozygous and  that  bear the  low 
susceptibility  H-2  d,  H-2  k,  and  Ig-1 a  alleles  should  exhibit  low  susceptibility.  The 
C3B6F1 strain  (C57BL/6 X  C3H/HeJ)Fa  bears the H-2  b/k, Ig-1 b/a genotype. When 
the incidence of muscular weakness and flaccid paralysis was measured for this strain, 
it was found that 42% of the animals immunized developed EMG (Table V). Although 
the frequency of EMG in the C3B6Fa strain was significantly greater (P-- 0.009) than 
the low-susceptibility parental strain C3H/HeJ (11% developed weakness and paral- 
ysis)  it was lower (P =  0.022)  than the high-susceptibility parental strain C57BL/6 
(71% developed muscular weakness and paralysis). Similarly the CB6F1 and B6CF1 
strains  (C57BL/6 ×  C3H/HeJ)F1 bear the H-2  bin, Ig-1 b/~ genotype. Because 40% of 
the  former  and  38%  of the  latter  developed  muscular  weakness  and  paralysis, 
heterozygosity leads to an intermediate responder. Again, the frequency of muscular 
weakness and  flaccid paralysis was  significantly greater  (P <  0.007)  than  the  low- 
susceptibility parental  type BALB/c (7% developed EMG)  and was less  (P =  0.068 
for CB6F1; P  =  0.039 for B6CF1) than the high-susceptibility parental type C57BL/ 
6  (71% developed EMG). These studies demonstrate that susceptibility to EMG is a 
heritable trait  and  indicate that  the heterozygous expression of the H-2  b and  Ig-I b 
alleles is less effective in conferring increased susceptibility to EMG than the homo- 
zygous case. It can be concluded therefore that susceptibility to EMG does not behave 
as a simple dominant or recessive factor. 
Discussion 
Several previous studies have considered the matter of differential susceptibility to 
EMG between inbred strains of mice immunized with  Torpedo AChR.  Fulpius et al. 
(21) immunized several strains of mice with AChR and found that although all strains 
tested (BALB/c, DBA/2, and NZB)  formed anti-AChR  antibodies, none developed 
EMG.  A  similar  result  was  reported  by  Heilbronn  et  al.  (22),  who  reported  that 
C57BL/6J  mice  immunized  with  Torpedo marmorata AChR  developed  anti-AChR 
antibodies but did not develop EMG. Fuchs et al. (4) reported that mice immunized 
with  T. californica AChR did develop paralysis and that  EMG was strain dependent 
in that some strains (e.g., AKR and C57BL/6) developed weakness and paralysis with 
a  much  greater  frequency than  others.  These  investigators  also  noted  that  mice 
bearing the H-28 and  H-2  q haplotypes appeared particularly resistant  to EMG and 
that mice of all strains tested developed high levels of anti-AChR antibodies. Studies 
in our laboratory (5)  suggested  that  all  mice can develop EMG and  demonstrated 514  GENETICS OF SUSCEPTIBILITY TO MYASTHENIA GRAVIS 
that susceptibility is strain dependent in that the probability with which an individual 
can be expected to develop muscular weakness and flaccid paralysis is much greater 
for some lineages than others. The observation that strains that share the same H-2 
haplotype differed in their susceptibility to EMG suggested that the H-2 locus alone 
does not  determine susceptibility or resistance to EMG.  Because the occurrence of 
muscular  weakness  and  paralysis  did  not  correlate with:  (a)  the  concentration  of 
antibodies reactive with mouse or T. californica  AChR,  (b) the presence of antibodies 
reactive with cell surface determinants of mouse AChR,  (c) the ability of antibodies 
to  increase  the  rate  of receptor degradation  on  cultured  muscle  cells,  or  (d)  the 
presence of antibodies reactive with antigenic determinants unique to mouse AChR, 
we concluded that if anti-AChR antibodies are responsible for the induction of EMG, 
then populations of particular structure and/or specificity are required. 
Christadoss et al. (23)  reported that the ability of lymph node cells obtained from 
congenic  mice  immunized  with  T.  californica  AChR  to  incorporate  [3H]thymidine 
when stimulated in vitro with limiting receptor was under H-2-1inked Ir gene control 
and concluded that the H-2  b, H-2  r, and H-2  j haplotypes were high responders; the H- 
2  a and H-2  f haplotypes were intermediate responders; and the H-2  k, H-28, H-2  v, and 
H-2  d haplotypes were  low  responders.  A  distinction  should  be  made  between  the 
strain-dependent differences in susceptibility described in these studies (23) and those 
described in the other studies mentioned (4, 5, 21, 22). The former probably reflects 
strain-dependent differences with respect to the threshold antigen dose necessary for 
the induction of proliferative response in lymph node cells, whereas the latter deal 
with the probability of weakness and paralysis after an anti-AChR immune response 
is well established. From the studies ofChristadoss et al. (23) it can be concluded that 
the threshold necessary for the induction of a proliferative response in cultured lymph 
node  cells  against  T.  californica  AChR  is  under  H-2-1inked  Ir  gene  control.  The 
conclusion  that  can  be  drawn  from  all  of the  other studies  described  is  that  the 
formation of anti-AChR antibodies in mice does not lead to the induction of EMG in 
an obligatory fashion. 
From our studies it can be concluded that the frequency with which mice develop 
muscular weakness and flaccid paralysis after immunization with T. californica  AChR 
is  determined,  to  a  great  extent, by regions  of the  genome that  regulate  immune 
responsiveness. Haplotypes of both the H-2 and the IgCH loci were identified that, in 
mice derived from dissimilar backgrounds, segregated with high or low susceptibility 
to EMG. The H-2  b, Ig-I b genotype was associated with high susceptibility to EMG in 
four strains (C57BL/6J, C67BL/10Sn, C.B20B, and CWB/20)  from three unrelated 
backgrounds  (C57BL, BALB, and C3H).  Congenic strains of mice that  differ from 
these high responders only in substitutions at the H-2 and IgCn loci exhibited reduced 
susceptibility.  For example,  the  BALB/c  (H-2  d,  Ig-1 a)  and  BALB/K  (H-2  k,  Ig-1 ~) 
strains exhibited low susceptibility (7-15% developed muscular weakness and paral- 
ysis), whereas their congenic partner, C.B20B  (H-2  b, Ig-lb), exhibited high suscepti- 
bility (67% developed muscular weakness and paralysis). Similarly, C3H/HeJ (H-2  k, 
Ig-1 *) was a low-susceptibility strain (11% developed muscular weakness and paraly- 
sis),  whereas its congenie partner, CWB/20  (H-2  b,  Ig-lb),  was  a  high-susceptibility 
strain (75% developed muscular weakness and paralysis). 
The importance of the  H-2  locus in determining susceptibility and  resistance to 
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it always segregated with increased susceptibility to EMG. The replacement of the H- 
2  d haplotype,  found  in  BALB/c, with  the  H-2  b haplotype, as  in  BALB.BI0, was 
accompanied by an  increase  in  the  frequency of muscular weakness and paralysis 
from  7%  (BALB/c)  to  50%  (BALB.B10).  Similarly,  the  replacement  of the  H-2 k 
haplotype, found in C3H/HeJ, by the H-2  b haplotype, found in C3H.SW/Sn, was 
accompanied by an  increase in  the frequency of muscular weakness and  paralysis 
from 11% (C3H/HeJ) to 60%  (C3H.SW/Sn). 
It was not possible, however, to attribute susceptibility or resistance to EMG to the 
H-2  locus  alone  because  replacement  of  the  high-susceptibility  H-2  b  haplotype 
(C57BL/10Sn) by the low-susceptibility H-2  a (A/J) and H-2  d (BALB/e) haplotypes 
reduced  the  frequency  of EMG  to  intermediate  values,  but  did  not  confer  low 
susceptibility. Thus 38% of the BI0.A/SgSn (H-2  a) and 47% of the B10.D2/nSn  (H- 
2  d) developed muscular weakness and paralysis as compared to 71% of the C57BL/ 
10Sn  (H-2b),  13%  of the A/J  (H-2a),  and  7%  of the  BALB/c  (H-2d).  In  addition, 
different strains of mice that bear the same H-2 haplotype were found to differ with 
respect to the frequency with which they developed muscular weakness and paralysis. 
For example, three strains that bear the H-2  k haplotype were examined; although the 
C3H/HeJ and BALB/k strains exhibited low susceptibility (11-15% developed mus- 
cular weakness and paralysis), the AKR strain exhibited intermediate susceptibility 
(50% developed muscular weakness and paralysis). Indeed, strains that share the H- 
2  a, H-2  d, and H-2  s haplotypes were also found to differ significantly with respect to 
the  frequency with  which  they developed  muscular  weakness  and  paralysis  after 
immunization with T. californica  AChR. From these studies, it can be concluded that 
although the H-2 locus exerts a significant effect on susceptibility to EMG, other loci 
are involved. 
Because the Ig-1 b haplotype was always found associated with increased suscepti- 
bility to EMG and was not present in any low-susceptibility strains, the possibility 
that the IgCn-locus-influenced susceptibility was considered. The SJL strain possessed 
the H-2  ~, Ig-1 b genotype and was the only high-susceptibility strain that did not bear 
the H-2  b haplotype. Replacement of the Ig-I b haplotype with the Ig-I ~ haplotype 
(SJA/9)  correlated with a  lowered incidence of EMG (from 64% for SJL to 30% for 
SJA/9)  and  indicated  that  the  IgCH  locus does  indeed  influence susceptibility to 
EMG.  This conclusion was  further supported  in  studies of mice derived  from the 
BALB  background  where  it  was  noted  that  BALB/c  (H-2 d,  Ig-1 ~)  exhibited  low 
susceptibility (7% became paralyzed), BALB.B 10 (H-2  b, Ig-1 ~) exhibited intermediate 
susceptibility  (50% became  paralyzed),  and  C.B20B  (H-2 b,  Ig-1 b)  exhibited  high 
susceptibility (67% became paralyzed). This result  suggested that  the difference in 
susceptibility between BALB.B10 and C.B20B is attributable to the Ig-1 b haplotype. 
This possibility was supported in studies of the C.B20 strain (H-2  d, Ig-1 b) where Ig-1 b 
replaces the BALB/c Ig-I a haplotype. This change correlated with an increase in the 
incidence of muscular weakness and paralysis from 7% (BALB/c H-2 d, Ig-1 *) to 30% 
(C.B20, H-2  d Ig-lb). 
The observation that the frequency of EMG in the BAB/14 strain (none became 
paralyzed) differed significantly from that of the C.B20 strain (30% became paralyzed; 
P-- .007) suggested that the linkage between allotype loci and susceptibility to EMG 
involves the IgVn region. Because this region contains the genes that determine the 
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linkage detected may reflect a  particular gene coding for an antibody specificity that 
is especially effective in  inducing  muscular weakness  and  paralysis.  Recent  studies, 
however,  have  demonstrated  that  BAB/14  mice  retain  at  least  one  Ig-1 b  idiotypic 
specificity, and  the possibility exists that  the lack of other Ig-I  b specificities can  be 
attributed to a  defect  in a  regulatory locus that  limits the expression of other Ig-I b 
alleles (24, 25). Thus,  the allotype linkage we have observed cannot  be attributed to 
the IgC8 or IgVn region with complete confidence. 
When  the data obtained in these studies is ranked  according to  the frequency of 
paralysis, a  pattern  of linkage  between  the  frequency  of muscular  weakness  and 
paralysis and the alleles of the H-2 and IgCn loci is suggested. As can be seen in Table 
VI, mice that bear the H-2  b, Ig-1 b genotype exhibit the greatest frequency of muscular 
weakness and paralysis (60-80%  became paralyzed). Mice that  bear the H-2 b, Ig-1 a 
genotype exhibited intermediate susceptibility (30-50% became paralyzed). Mice that 
possess the H-2  x, Ig-1 b genotype (where x corresponds to the H-2  a, H-2  a, H-2 k, or H- 
2  ~ haplotypes) also exhibited intermediate susceptibility (30-50% became paralyzed). 
Mice that bear the H-2  x, Ig-1 a genotype (where x corresponds to the H-2  d, H-2  k, or H- 
2  ~ haplotypes) exhibited the lowest frequency of muscular weakness and paralysis (0- 
15%  became  paralyzed). Mice that  are heterozygous at  the H-2  and  IgCn  loci and 
that  bear  the  H-2  b/d,  Ig-I  b/a  or  H-2  b/k,  Ig-1 b/a  genotypes  exhibited  intermediate 
susceptibility in  that  40-50%  became  paralyzed. Thus,  the  frequency  of muscular 
TABLE  VI 
Pattern of Susceptibility  to EMG after Immun,zation  with  T. californica AChR 
Frequency  Rank 
Genotype  Strain  Background  of  order  Classification 
paralysis 
H-2  b, Ig-I  s  CWB/20  C3H  0.75  1  High 
C57BL/6  C57BL  0.71  2  High 
C57BL/10Sn  C57BL  0.70  3  High 
C.B20B  BALB  0.67  4  High 
H-2  b, Ig-1  a  C3H.SW/Sn  C3H  0.60  6  High 
C57BL/Ka.Ig  a  C57BL  0.53  7  Intermediate 
BALB.BI0  BALB  0.50  8  Intermediate 
H-2X,  * Ig-1  b 
H.2X/h,* Ig_l"/b 
H-2X,  * Ig-1  a 
SJL/J  SJL  0.64  5  High 
BI0.D2/nSn  C57BL  0.47  9  Intermediate 
BI0.A/SgSn  C57BL  0.38  13  Intermediate 
C.B20  BALB  0.29  14  Intermediate 
C3B6FI  C3H/C57BL  0.42  10  Intermediate 
CB6F1/J  BALB/C57BL  0.40  11  Intermediate 
B6CFj  C57BL/C3H  0.38  12  Intermediate 
SJA/9  SJL  0.27  15  Intermediate 
BALB.K  BALB  0.15  16  Low 
C3H/HeJ  C3H  0.1 l  17  Low 
BALB/c  BALB  0.07  18  Low 
*x =  a  for BI0.A/SgSn; d  for B10.D2/nSn,  BALB/c, CB6FI/J, B6CF~, and C.B20; k for C3H/HeJ, 
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weakness and flaccid paralysis after immunization with  T. californica  AChR is deter- 
mined by at least two loci, and particular haplotypes of the H-2 and IgCa correlate 
with increased susceptibility. The strains that are exceptions to the pattern described 
may  be  accounted  for in  several  ways.  First,  they  may  reflect  uncertainties  with 
respect  to  the  size  of the  H-2  and  IgCn  region  arising  from  the  lack  of suitable 
markers. Alternatively, they may reflect sampling errors; although it is highly unlikely 
(P <  0.005)  that  high-susceptibility strains could be mistaken  for low-susceptibility 
strains, the probability that high or low responders could be mistaken for intermediate 
responders is somewhat greater. In most cases, however, such an error would actually 
support the conclusions we have drawn and would not change the interpretation of 
the results. A third possibility is that other loci, yet to be identified, participate along 
with the H-2 and IgCa loci in determining susceptibility. 
The observation that susceptibility to EMG segregates with H-2 and IglZH haplo- 
types was  unexpected.  Such  linkage is  usually  detected only with  simple antigens 
possessing few antigenic determinants or large multideterminant  antigens  given in 
limiting  doses.  Because  AChR  (2.0  ×  105-2.5  ×  105  mol  wt)  is  neither  a  simple 
antigen, nor was it given the limiting dosages, one would not expect to see linkage 
between the anti-AChR immune response and immune response loci because all mice 
should be capable of recognizing at least some of the many antigenic determinants 
that a molecule the size of AChR must possess.  This expectation proved to be correct 
because mice of all strains tested developed high concentrations of antibodies reactive 
with mouse  and  T.  californica  AChR  (average  concentration  of antibodies  to  T. 
californica AChR, 2.2 ×  10  -~ M; average concentration of antibodies to mouse AChR, 
3.4 ×  10  -7 M; [5]). Thus, the linkage we have found is only between the development 
of muscular weakness and immune response loci, and does not apply to the magnitude 
of the humoral immune response to mouse or T. californica AChR. The H-2 and IgCH 
linkage may be accounted for by several alternative mechanisms: (a) The linkage may 
reflect antigenic specificities of T  cell- or B cell-derived effector molecules that  are 
particularly  effective  (or  necessary)  for  the  induction  of muscular  weakness  and 
paralysis.  (b)  The linkage may reflect regulatory mechanisms  that  favor particular 
modes of immune attack  (e.g.,  antibody-dependent cytotoxicity, killer T  cells, com- 
plement-mediated cytotoxicity). (c) Mouse AChR or neuromuscular junctions may be 
polymorphic and their structure may be determined by alleles linked to the H-2 or 
IgCH regions. 
The hypothesis that not all antibodies reactive with autologous AChR can induce 
myasthenia  gravis  and  that  particular  spccificities are  required,  may  account  for 
several unexplained aspects of human  myasthenia gravis:  (a)  Although  90%  of all 
myasthcnics possess humoral antibodies reactive with AChR,  there is an  imperfect 
relationship betwccn the concentration of anti-receptor antibodies and the sevcrity of 
the disease (26-28). This observation may be accounted for if it is "assumed  that only 
a  limited population of anti-receptor antibodies can induce muscular weakness and 
flaccid paralysis. (b) Only 12% of neonates from myasthenic mothers develop neonatal 
myasthenia (29), and nonmyasthcnic neonates possessing anti-AChR antibodies have 
been reported (30). This observation can also be explained by assuming that  popu- 
lations of a  particular structure and/or specifrcity are required for the induction of 
myasthenia. (c) Appel and Elias (3 l) have reported that some myasthenics undergoing 
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of anti-AChR antibodies that can increase the rate of AChR degradation on cultured 
muscle  cells.  This  observation  also  is  consistent  with  the  idea  of myasthenogenic 
specificities  and  suggests  a  distinction  between  antibodies  that  induce  myasthenia 
gravis and those that increase the rate of AChR degradation.  Such a distinction was 
suggested  in  our  studies  of  EMG  (5)  where  many  animals  that  did  not  exhibit 
weakness and paralysis were found to possess antibodies that could increase the rate 
of AChR degradation on cultured muscle cells. 
In conclusion, immunization of mice with T. californica AChR induces the formation 
of anti-AChR antibodies and often results in extreme muscular weakness and flaccid 
paralysis closely resembling the human disease myasthenia gravis; Knowledge of the 
concentration of antibodies reactive with mouse or T. californica  AChR, the presence 
of antibodies that are able to increase the rate of AChR degradation, or the presence 
of antibodies reactive with determinants unique to mouse AChR does not permit an 
estimation of the probability of muscular weakness and paralysis. However, knowledge 
of the strain  of mouse or of the  haplotypes present  at  the  H-2 and  IgCn loci  does 
allow for an estimation of paralysis and provides strong evidence that susceptibility to 
EMG is a heritable trait linked to regions of the mouse genome that regulate immune 
responsiveness. That one genotype (H-2  b, Ig-1  b) was associated with high susceptibility 
on three dissimilar backgrounds suggests that  despite the complex mechanisms that 
underlie neuromuscular transmission and muscle contraction, it is the alleles present 
at the H-2 locus on chromosome 17 and the IgCn locus on chromosome 12 that are 
of major importance  in  determining  whether  or  not  a  mouse  immunized  with  T. 
californica  AChR will become paralyzed. At this time, it is not known whether the H- 
2-  and  IgCn-linked  effects  on  susceptibility  are  additive  or  synergistic,  and  the 
possibility  remains  that  additional  alleles  at  these  and  other  loci  may  modulate 
susceptibility or resistance to EMG. Further genetic analysis employing recombinant- 
inbred strains of mice and progeny resulting from backcrosses of FI mice with parental 
types should help to clarify these issues. 
Summary 
Mice immunized with acetylcholine receptor (AChR)  purified from Torpedo califor- 
nica  form anti-AChR  antibodies  and  often  develop muscular  weakness and  flaccid 
paralysis closely resembling the  human  disease  myasthenia  gravis.  This  condition, 
termed  experimental  myasthenia  gravis  (EMG),  is  strain  dependent  in  that  the 
frequency of paralysis is much greater in some strains than in others.  Differences in 
the  frequency of EMG might  result  from differences in  the  immune system or the 
neuromuscular junction.  In  these  studies,  we  have  identified  two  loci,  the  major 
histocompatibility  complex  (H-2)  region  on  chromosome  17  and  the  region  that 
contains the structural genes for the constant region of immunoglobulin heavy chains 
(IgCn'region)  on  chromosome  12,  which  significantly  effect  the  probability  with 
which  a  mouse  immunized  with  T.  californica  AChR  can  be  expected  to  become 
paralyzed. One genotype (H-2  b, Ig-1  b) correlated with high susceptibility to EMG in 
four strains with three dissimilar backgrounds. These studies demonstrate that suscep- 
tibility to EMG is a  heritable trait determined  by at  least two distinct  loci that are 
linked to regions of the mouse genome that regulate immune responsiveness. 
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